137 related articles for article (PubMed ID: 34098565)
41. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
42. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
43. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
44. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH
Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706
[TBL] [Abstract][Full Text] [Related]
45. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
[TBL] [Abstract][Full Text] [Related]
46. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
47. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
48. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
49. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
[TBL] [Abstract][Full Text] [Related]
50. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer.
Wang X; Liu H; Maimaitiaili A; Zhao G; Li S; Lv Z; Wu D; Shi A; Guan X; Jia H; Li M; Song D; Kang L; Han B; Fu T; Yang M; Zhu Z; Du Y; Song Y; Hong J; Fan Z
Mol Genet Genomic Med; 2019 Jun; 7(6):e677. PubMed ID: 30968603
[TBL] [Abstract][Full Text] [Related]
51. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
53. Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
Sun Y; Kang E; Baek H; Jung J; Hwang E; Koo J; Kim EK; Kim SW
Jpn J Clin Oncol; 2015 Jun; 45(6):527-32. PubMed ID: 25838294
[TBL] [Abstract][Full Text] [Related]
54. [Hereditary breast carcinomas pathologist's perspective].
Vincent-Salomon A; Bataillon G; Djerroudi L
Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
[TBL] [Abstract][Full Text] [Related]
55. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
[TBL] [Abstract][Full Text] [Related]
56. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
57. A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.
Sahin I; Saat H
Mol Biol Rep; 2021 Jun; 48(6):5057-5062. PubMed ID: 34146199
[TBL] [Abstract][Full Text] [Related]
58. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
59. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
Kang E; Seong MW; Park SK; Lee JW; Lee J; Kim LS; Lee JE; Kim SY; Jeong J; Han SA; Kim SW;
Breast Cancer Res Treat; 2015 May; 151(1):157-68. PubMed ID: 25863477
[TBL] [Abstract][Full Text] [Related]
60. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
Moreno M; Oliveira JS; Brianese RC; de Castro DG; Sanches SM; Torrezan GT; Santiago KM; De Brot M; Cordeiro de Lima VC; Baroni Alves Makdissi F; Casali Da Rocha JC; Calsavara VF; Carraro DM
Cancer Med; 2023 Aug; 12(15):16129-16141. PubMed ID: 37485802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
